Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
A band of heavy rain is heading for the UK, threatening to make the May Bank Holiday a washout, the Met Office has warned.
Headteachers could strike in protest at government plans to force schools to become academies
Tonight it'll become dry and clear for most parts of Britain.